A Composite Dermal Filler Comprising Cross-Linked Hyaluronic Acid and Human Collagen for Tissue Reconstruction
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
In this study, we developed a composite filler comprising cross-linked hyaluronic acid (HA) and human collagen (COL) derived from the human umbilical cord with the aim of improving its biocompatibility and longevity compared with commercially available fillers. After HA/ COL composite fillers were made in two different ratios (10:1 and 5:1), the physical properties of the fillers were evaluated. The interior morphologies and in vivo weight change of these hydrogels were also characterized at 1-16 weeks after injection into mice. To evaluate their biocompatibility and durability in vivo, we injected the composite fillers into nude mice subcutaneously. The variations of injected gel weight were measured and compared with the commercial dermal fillers (Restylane and TheraFill). The composites showed improved or similar physical properties (complex viscosity of 19-22 × 105 cP, and injection force of 10- 12 N) over the commercial dermal fillers. Sixteen weeks following the injection, the ratio of remaining composite filler weight to initial weight (75.5 ± 16.9%; 10:1) was shown to be greater than that of the commercial fillers (43.2 ± 8.1%, Restylane; 12.3 ± 5.3%, TheraFill). In addition, immunohistochemical analysis with angiogenesis-related markers such as isolectin and vWF revealed newly formed blood vessels and cellular influx into the composite filler, which were not observed in the other fillers. These results clearly suggest that the HA/COL composite filler is a superior candidate for soft tissue reconstruction. The filler we developed may be a suitable candidate as an injectable dermal filler for tissue augmentation in humans.
Abstract
In this study, we developed a composite filler comprising cross-linked hyaluronic acid (HA) and human collagen (COL) derived from the human umbilical cord with the aim of improving its biocompatibility and longevity compared with commercially available fillers. After HA/ COL composite fillers were made in two different ratios (10:1 and 5:1), the physical properties of the fillers were evaluated. The interior morphologies and in vivo weight change of these hydrogels were also characterized at 1-16 weeks after injection into mice. To evaluate their biocompatibility and durability in vivo, we injected the composite fillers into nude mice subcutaneously. The variations of injected gel weight were measured and compared with the commercial dermal fillers (Restylane and TheraFill). The composites showed improved or similar physical properties (complex viscosity of 19-22 × 105 cP, and injection force of 10- 12 N) over the commercial dermal fillers. Sixteen weeks following the injection, the ratio of remaining composite filler weight to initial weight (75.5 ± 16.9%; 10:1) was shown to be greater than that of the commercial fillers (43.2 ± 8.1%, Restylane; 12.3 ± 5.3%, TheraFill). In addition, immunohistochemical analysis with angiogenesis-related markers such as isolectin and vWF revealed newly formed blood vessels and cellular influx into the composite filler, which were not observed in the other fillers. These results clearly suggest that the HA/COL composite filler is a superior candidate for soft tissue reconstruction. The filler we developed may be a suitable candidate as an injectable dermal filler for tissue augmentation in humans.
참고문헌 (30)
- Alijotas-Reig J, "Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers", Semin. Arthritis Rheum, 43, pp.241~258 (2013)
- Allemann IB, "Hyaluronic acid gel (Juvéderm™)preparations in the treatment of facial wrinkles and folds", Clin. Interv. Aging, 3, pp.629~656 (2008)
- Baumann LS, "The treatment of bovine collagen allergy with cyclosporin", Dermatol. Surg, 25, pp.247~249 (1999)
- Beasley KL, "Hyaluronic acid fillers: a comprehensive review", Facial Plast. Surg, 25, pp.86~94 (2009)
- Burgess CM, "Principles of soft tissue augmentation for the aging face", Clin. Interv. Aging, 1, pp.349~355 (2006)
- Carruthers J, "Mad cows, prions, and wrinkles", Arch. Dermatol, 138, pp.667~670 (2002)
- Cena RB, "Effects of crosslinked dextran in hydroxylpropyl methylcellulose on soft tissue augmentation in rats", J. Biomed. Mater. Res. B Appl. Biomater, 102, pp.131~140 (2014)
- Davidenko N, "Collagen-hyaluronic acid scaffolds for adipose tissue engineering", Acta Biomater, 6, pp.3957~3968 (2010)
- Eppley BL, "Effects of a positively charged biomaterial for dermal and subcutaneous augmentation", Aesthet. Plast. Surg, 18, pp.413~416 (1994)
- Falcone SJ, "Crosslinked hyaluronic acid dermal fillers: a comparison of rheological properties", J. Biomed. Mater. Res. A, 87, pp.264~271 (2008)
- Grunebaum LD, "The risk of alar necrosis associated with dermal filler injection", Dermatol. Surg, 35, pp.1635~1640 (2009)
- Hersel U, "RGD modified polymers: biomaterials for stimulated cell adhesion and beyond", Biomaterials, 24, pp.4385~4415 (2003)
- 허선영, "A Case of Complication after MatridexⓇ Injection", Annals of Dermatology, 22(1), pp.81~84 (2010), 대한피부과학회
- Kablik J, "Comparative physical properties of hyaluronic acid dermal fillers", Dermatol. Surg, 35, pp.302~312 (2009)
- Kim KO, "Wound healing properties of a 3-D scaffold comprising soluble silkworm gland hydrolysate and human collagen", Colloids Surf. B, 116, pp.318~326 (2014)
- KIM, SAE-JIN, "A Novel Approach to the Production of Hyaluronic Acid by Streptococcus zooepidemicus", Journal of Microbiology and Biotechnology, 16(12), pp.1849~1855 (2006), 한국미생물·생명공학회
- Kim SM, "Alternative xeno-free biomaterials derived from human umbilical cord for the self-renewal ex-vivo expansion of mesenchymal stem cells", Stem Cells Dev, 22, pp.3025~3038 (2013)
- Kong, Min Kyung, "Evaluation of a Pretreatment Method for Two-Dimensional Gel Electrophoresis of Synovial Fluid Using Cartilage Oligomeric Matrix Protein as a Marker", Journal of Microbiology and Biotechnology, 22(5), pp.654~658 (2012), 한국미생물·생명공학회[DOI]
- La Gatta A, "Comparative analysis of commercial dermal fillers based on crosslinked hyaluronan: physical characterization and in vitro enzymatic degradation", Polym. Degrad. Stabil, 96, pp.630~636 (2011)
- Laurent TC, "Hyaluronan", FASEB. J, 6, pp.2397~2404 (1992)
- Na K, "Certification of fibroblast cell adhesion and spreading mediated by Arg-Gly-Asp (RGD) sequence on thermo-reversible hydrogel", J. Microbiol. Biotechnol, 11, pp.922~927 (2001)
- Natarajan V, "Preparation and properties of tannic acid cross-linked collagen scaffold and its application in wound healing", J. Biomed. Mater. Res. B Appl. Biomater, 101, pp.560~567 (2013)
- 류종석, "Prions and Prion Diseases: Fundamentals and Mechanistic Details", Journal of Microbiology and Biotechnology, 17(7), pp.1059~1070 (2007), 한국미생물·생명공학회
- Shin JS, "The effects of fetal bovine serum, epidermal growth factor, and retinoic acid on adult rat islets embedded in collagen gels", J. Microbiol. Biotechnol, 9, pp.150~156 (1999)
- Simoni RD, "The discovery of hyaluronan by Karl Meyer", J. Biol. Chem, 277, pp.e27~ (2002)
- Smith SR, "Duration of wrinkle correction following repeat treatment with Juvederm hyaluronic acid fillers", Arch. Dermatol. Res, 302, pp.757~762 (2010)
- Tang S, "Incorporation of hyaluronic acid into collagen scaffolds for the control of chondrocyte-mediated contraction and chondrogenesis", Biomed. Mater, 2, pp.S135~ (2007)
- Tang S, "Fabrication and characterization of porous hyaluronic acid-collagen composite scaffolds", J. Biomed. Mater. Res. A, 82, pp.323~335 (2007)
- Verpaele A, "Restylane SubQ, a non-animal stabilized hyaluronic acid gel for soft tissue augmentation of the mid and lower face", Aesthet. Surg. J, 26, pp.S10~S17 (2006)
- Yoon ES, "Advantages of the presence of living dermal fibroblasts within restylane for soft tissue augmentation", Ann. Plast. Surg, 51, pp.587~592 (2003)